Journal article

Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child.

Nicole Ritz, Roland A Ammann, Carmen Casaulta Aebischer, Mathias Gugger, Katia Jaton, Ralph A Schmid, Christoph Aebi

Eur J Pediatr | Published : 2005

Abstract

UNLABELLED: Voriconazole is increasingly used as a first-line agent for empirical antifungal therapy of prolonged febrile neutropenia in paediatric cancer patients. We describe the case of a 9-year-old patient with stage IV Burkitt lymphoma, who developed pulmonary and splenic zygomycosis while receiving voriconazole for persistent febrile neutropenia. The causative agent, Absidia corymbifera, was identified by broad-range fungal PCR in a lung biopsy sample. The patient was successfully treated with a combination of partial resection of the left upper lobe and antifungal therapy with high-dose liposomal amphotericin B followed by oral itraconazole as demonstrated by resolving pulmonary infil..

View full abstract